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Abstract
Background: Breast pain and tenderness affects 70% of women at some time. These symptoms
have been attributed to stretching of the nerves with increase in breast size, but tissue mechanisms
are poorly understood.
Methods: Eighteen patients (n = 12 breast reduction and n = 6 breast reconstruction) were
recruited and assessed for breast pain by clinical questionnaire. Breast skin biopsies from each
patient were examined using immunohistological methods with specific antibodies to the capsaicin
receptor TRPV1, related vanilloid thermoreceptors TRPV3 and TRPV4, and nerve growth factor
(NGF).
Results: TRPV1-positive intra-epidermal nerve fibres were significantly increased in patients with
breast pain and tenderness (TRPV1 fibres / mm epidermis, median [range] – no pain group, n = 8,
0.69 [0–1.27]; pain group, n = 10, 2.15 [0.77–4.38]; p = 0.0009). Nerve Growth Factor, which up-
regulates TRPV1 and induces nerve sprouting, was present basal keratinocytes: some breast pain
specimens also showed NGF staining in supra-basal keratinocytes. TRPV4-immunoreactive fibres
were present in sub-epidermis but not significantly changed in painful breast tissue. Both TRPV3
and TRPV4 were significantly increased in keratinocytes in breast pain tissues; TRPV3, median
[range] – no pain group, n = 6, 0.75 [0–2]; pain group, n = 11, 2 [1-3], p = 0.008; TRPV4, median
[range] – no pain group, n = 6, [0–1]; pain group, n = 11, 1 [0.5–2], p = 0.014).
Conclusion: Increased TRPV1 intra-epidermal nerve fibres could represent collateral sprouts, or
re-innervation following nerve stretch and damage by polymodal nociceptors. Selective TRPV1-
blockers may provide new therapy in breast pain. The role of TRPV3 and TRPV4 changes in
keratinocytes deserve further study.
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Breast pain is a common problem, which can affect up to
70% of women [1]. Breast pain or mastalgia can be cycli-
cal or non-cyclical. The cyclical type of breast pain has
been attributed to sex hormonal changes through the
menstrual cycle that may increase the size of the breast tis-
sue, which stretches the internal structures and causes
pain or soreness. Numerous studies have demonstrated
variation in pain perception during the menstrual cycle
[2-5]. Heat sensitivity is increased in the luteal (17–22)
phase of the menstrual cycle [6] and lowest in the perio-
vulatory phase (day 12–16), but other studies have shown
variation at other times in the cycle. Non-cyclical breast
pain can be caused by hormonal influences particularly
oestrogen, and other causes such as macromastia, local
infection or inflammation; rarely, breast cancer can
present as breast pain. Macromastia may cause areas of
numbness in the breast and problems with nipple erectile
function, which is thought to be related to the stretching
of the nerve supply with increase in breast size [7]. Post-
surgical breast pain is also a significant entity, with about
50% of women who undergo mastectomy suffering from
chronic pain one year after their operation [8,9].
The mechanisms of breast pain in the majority of women
are not well understood at the cellular or molecular level.
We hypothesized a relationship between clinical breast
pain, nerve growth factor (NGF) and its regulated ion
channels or receptors expressed by nociceptor fibres.
Estrogens upregulate NGF receptor mRNA in sensory neu-
rons [10], and enhance the proliferative effects of NGF
[11,12]. As NGF is a key molecule that determines the sen-
sitivity of nociceptors in humans [13] and animal models
[14], sex hormonal influences could be responsible for
altered NGF activity during the menstrual cycle, leading to
cyclical breast soreness or pain. NGF expression is also
increased by inflammation, and this is responsible for the
collateral nerve fibre sprouting and hypersensitivity of
nociceptor fibres associated with inflammation. The
hypersensitivity is, in part, mediated via the capsaicin or
vanilloid receptor 1 (TRPV1), which is required for ther-
mal hyperalgesia in rodents [15,16], and is activated by
heat pain. Thermal hyperalgesia can occur during the
menstrual cycle and it is well known that the core body
temperature alters during the cycle (this is a qualitative
test for ovulation), and thus heat conductance and per-
ception and tolerance of heat alters during the cycle [2,6].
The TRPV1 receptor is activated also by the products of
inflammation. We have therefore studied TRPV1-express-
ing nerve fibres and NGF in skin from women with and
without breast pain and tenderness. The recently discov-
ered vanilloid thermoreceptors TRPV3 and TRPV4, which
are also expressed by sensory fibres and activated by
warmth, were also studied [17,18].
Methods
Patients
Eighteen patients were recruited (n = 12 breast reduction
for macromastia; n = 6 breast reconstruction) at Chelsea
and Westminster, Charing Cross, Ravenscourt Park Hospi-
tals in London and Broomfield Hospital in Essex were
recruited. Breast reduction patients had no previous sur-
gery. The breast reconstruction patients had Latissimus
dorsi flap reconstructions after previous mastectomies,
and had implants. Patients below 18 years or above 70
years, with any local skin inflammation, infection or can-
cerous skin changes were excluded. The Research Ethics
Committee of Hammersmith Hospitals Trust and Mid
Essex Hospitals Trust gave ethical permission for the
study. Informed consent was obtained prior to the clinical
examination and questionnaire administration.
Clinical pain assessment
Age, parity, height, weight and menstrual data were col-
lected. Details of current surgery, any previous breast sur-
gery and breast disease were also recorded. A
questionnaire which included questions on breast and
period pain was administered, a diagram to indicate pain-
ful and tender areas and the 78 pain descriptors from the
McGill Pain Questionnaire [19] were produced, along
with a 10 cm unmarked visual analogue scale (VAS). The
presence of breast pain was defined from the results of the
Breast Pain Questionnaire using the total Pain Rating
Index (PRI (total)) [19] and VAS scores marked by the
patient in centimetres being more than zero to identify
those patients with breast pain. Only two patients were
taking simple analgesia for breast pain.
Immunohistochemistry
Full thickness skin biopsies were collected from each
patient along the incision line of about 2 mm depth. Sam-
ples were coded, frozen on site and stored at -70°C. The
skin samples were mounted in embedding medium (Tis-
sue-Tek OCT compound, Sakura Finetek, USA). Frozen
tissue sections (10 µm) were collected onto poly-L-lysine-
coated (Sigma Poole Dorset UK) glass slides and post-
fixed in freshly prepared, 4% w/v paraformaldehyde in
phosphate buffered saline (PBS; 0.1 M phosphate; 0.9%
w/v saline; pH 7.3). After washing in PBS, endogenous
peroxidase was blocked by incubation with 0.3% w/v
hydrogen peroxide in methanol. After a further wash in
PBS the tissue sections were incubated overnight with
affinity purified antibodies to TRPV1 (polyclonal rabbit
anti-TRPV1; GlaxoSmithKline, Harlow, UK; 1/5000; 1/
10,000), TRPV3 (polyclonal rabbit anti-TRPV3; Glaxo-
SmithKline, Harlow, UK; 1/1000), TRPV4 (polyclonal
rabbit anti-TRPV4; GlaxoSmithKline, Harlow, UK; 1/250;
1/1000), recombinant human NGF (polyclonal rabbit
anti-NGF; Genentech, San Francisco, USA; 1/4000) or
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200 kD, 70 kD and 57 kD; DAKO cytomation Cambs.,
UK, 1/50,000; Novocastra, Newcastle upon Tyne, UK, 1/
500). Methodological controls included omission of pri-
mary antibodies, or their replacement with pre-immune
serum. Specificity of antibodies has been described in pre-
vious publications [18,20]. Sites of antibody attachment
were revealed using biotinylated goat anti- rabbit or bioti-
nylated horse anti-mouse IgG (Vector Laboratories, High
Wycombe, Bucks., U.K.) and nickel-enhanced, immu-
noperoxidase (avidin-biotin complex – ABC elite; Vector
Laboratories, High Wycombe, Bucks., U.K.). Nuclei were
counterstained with 0.1% w/v aqueous neutral red. The
intensity of NGF immunostaining was graded on a scale 0
– 3 where 0 = negative or no immunoproduct, 1 = weak
immunoproduct, 2 = intermediate intensity immuno-
product and 3 = intense immunoproduct. Intra-epidermal
and sub-epidermal TRPV1-, TRPV4 or neurofilament –
positive fibres were counted and the length and thickness
of the epidermis was measured using a calibrated micro-
scope, eyepiece graticule. Similarly, fibres that extended
through the epidermis were counted, along with arboris-
ing "clusters" of fibres. The two observers who performed
the histological studies were blinded with regard to clini-
cal pain scores.
Statistical analyses
A non-parametric, two tailed test (Mann Whitney U) was
used. Commercially available statistical software was used
to perform the test (Prism 3™).
Results
Clinical pain assessment
Pain Rating Indices (PRI) and Visual Analogue Scores
(VAS) were used to group patients with (n = 10) and with-
out (n = 8) breast pain: pain group; PRI -Median (range)
12 (4–30); Mean (SEM) 13.44(3.07) and VAS – Median
(range) 5(3.7–6.7); Mean (SEM) 5.14(0.31)]; in patients
without breast pain, PRI and VAS were zero. Only 2
patients reported thermal pain descriptors (burning, hot),
while most reported ache and tenderness. The numbers of
breast reduction and reconstruction patients with pain
were 7 out of 12 and 3 out of 6 respectively, and all
reported pain of duration greater than 6 months. The
presence (n = 8) or absence (n = 10) of dysmenorrhoea
was also recorded. There was no association between
breast pain and the presence of dysmenorrhoea.
Immunostaining
TRPV1
TRPV1-immunoreactive fibres were present mainly in the
sub-epidermis in normal (pain free) skin (Fig. 1A). In
breast pain, TRPV1-immunoreactive fibres appeared to be
more abundant in the epidermis and frequently seen to
pass along the junction of the stratum corneum (intra-epi-
dermal fibres – IEF; Fig. 1B, Ci, ii) often with multiple
fibres (fibre "clusters"; Fig. 1Di, ii- arrows). Intra-epider-
mal fibres and fibre "cluster" counts/millimetre of epithe-
lium were significantly higher in patients with breast pain
(Table 1; Fig. 2). This significance was maintained despite
exclusion of patients with previous breast surgery (i.e. the
breast reconstruction patients; Pain, n = 7; No Pain, n = 5;
p = 0.0303). While some specimens from pain patients
showed thinning of the epidermis, this was not so overall
for the pain group (Table 1).
TRPV1-immunoreactive nerve fibres in breast skinFigure 1
TRPV1-immunoreactive nerve fibres in breast skin. 
(A) Normal, control skin : TRPV1-immunoreactive nerve 
fibres (small arrows) in the sub-epidermis. (B) Painful skin 
(macromastia patient): intra-epidermal, TRPV1-immunoreac-
tive nerve fibre (arrow) deriving from a large, sub-epidermal 
fascicle and extending to the stratum corneum. (Ci) Painful 
skin (breast reconstruction patient): TRPV1-immunoreactive 
intra-epidermal fibres passing along the junction between the 
epidermis and stratum corneum (Cii-enlarged area from Ci). 
(Di) Painful skin (macromastia patient): multiple branching, 
TRPV1-immunoreactive intra-epidermal nerve fibres 
(arrows) extending to the stratum corneum (Dii-enlarged 
area from Di). Large double arrows indicate relative epider-
mal thickness. Scale bars: A, B, C(i), D(i) = 50 µm; C(ii), D(ii) 
= 10 µm.Page 3 of 9
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TRPV3 immunoreactivity was detected in basal keratinoc-
ytes and occasional suprabasal cells throughout the epi-
dermis. Quantification of immunostaining showed a
significant (*P = 0.011) increase with breast pain (Fig. 3).
TRPV3-immunoreactivity was not detected in skin nerve
fibres in this study.
TRPV4
Basal keratinocytes also displayed TRPV4 immunoreactiv-
ity in groups of cells which were particularly strong at the
apex of dermal papillae, where immunoreactivity
appeared most strong at the cell membrane junction (Fig
4). Quantification of immunostaining showed a signifi-
cant (p < 0.03) increase with breast pain (Fig. 4). TRPV4
immunoreactivity was also detected in fine nerve fibres
scattered through the sub-epidermis, and showed a trend
(p = 0.402) for increased frequency in painful subjects
(Fig 4).
NGF
NGF immunoreactivity was present in basal keratinocytes
in all samples (Fig 5Ai, ii) with little difference in intensity
between pain and no pain specimens (Table 1). In some
pain specimens the epidermis appeared to be thinner, and
there was evidence of NGF expression in suprabasal as
well as basal keratinocytes (Fig 5Bi and 5ii, – arrows),
which correlated with the presence of TRPV1positive
fibres (seen in a serial section from the same case shown
in Fig 1B).
Nerve marker (neurofilaments)
Neurofilaments showed nerve fibres in sub-epidermal
and dermal regions only but no significant changes were
detected between groups (Table 1).
Table 1: Histology results
Patients with no breast pain (N = 8) Patients with breast pain (N = 10) P-Mann Whitney Test
Intra-epidermal Median (range) Median (range)
TRPV1 intra-epidermal fibres 0.69 (0.00 – 1.27) 2.15 (0.77 – 4.38) 0.0009**
TRPVR1 fibre "clusters" 0.15 (0.00 – 0.27) 0.37 (0.00–0.85) 0.0085*
Sub-epidermal
TRPV1 fibres 2.98 (1.59–4.04) 3.79 (0.63 – 5.92) 0.1457
Neurofilament fibres 3.38 (0.83 – 5.92) 2.95 (0.94 – 4.95) 0.7618
NGF staining 2.5 (1.0–3.0) 2.38 (1.0–3.0) 0.5726
Epidermal Thickness (mm) 0.04 (0.02 – 0.12) 0.04 (0.03 – 0.05) 0.9654
Quantification of TRPV1-immunoreactive, intra-epidermal fibres and breast painFigure 2
Quantification of TRPV1-immunoreactive, intra-epi-
dermal fibres and breast pain. Scattergrams show 
TRPV1-immunoreactivity in (A) intra-epidermal fibres and 
(B) intra-epidermal fibre "clusters" in patients with and with-
out breast pain.Page 4 of 9
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TRPV3-immunoreactivity in breast skin. TOP PANELS: TRPV3-immunoreactive keratinocytes mostly in basal layer and 
graded from grade 0/negative (top left) to grade 3/strong staining (bottom right). Scale bar = 100 µm BOTTOM PANEL: Scat-
tergram showing grading assessment and a significant increase (*P < 0.05) of TRPV3 immunoreactivity in patients with pain.Page 5 of 9
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TRPV4-immunoreactivity in breast skin. TOP FOUR PANELS: TRPV4-immunoreactivity in keratinocytes mostly at the 
cell membrane and graded from grade 0/negative (top left) to grade 3/strong staining (bottom right). Scale bar = 100 µm MID-
DLE PANEL: Fine, sub-epidermal, TRPV4-immunoreactive fibres (arrows). Scale bar = 100 µm BOTTOM PANELS: Scatter-
grams showing grading assessment of sub-epidermal fibres (left panel) and keratinocytes (right panel) significantly increased (*P 
< 0.05) in patients with pain.Page 6 of 9
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While breast pain and tenderness is a common problem,
in the majority of women the mechanisms underlying
breast pain are poorly understood. Our study focused on
Nerve Growth Factor (NGF) and the expression of the cap-
saicin receptor 1 (TRPV1) in nociceptor fibres, as these are
key molecules in pain and hypersensitivity. Our finding,
that TRPV1-positive intra-epidermal fibres were signifi-
cantly increased in patients with breast pain and tender-
ness, is both novel and important. The increased and
abnormal "clusters" of intra-epidermal fibres were shown
in patients who had no previous breast surgery, and no
known episodes of mastitis. Hence this may be a surrogate
marker for "idiopathic" or macromastia related breast
pain in some patients. Studies are in progress to correlate
changes in TRPV1 nerve fibres with quantitative sensory
perception thresholds.
The cause of the increased intra-epidermal fibres is not
known. Given the trend to thinning of the epidermis, nor-
mally associated with denervation [21], in the biopsies
from some patients with breast pain, the increased intra-
epidermal fibres here may represent nerve fibre sprouts
following cutaneous terminal damage. The intra-epider-
NGF-immunoreactivity in breast skinFigure 5
NGF-immunoreactivity in breast skin. (Ai) Normal, control skin: NGF-immunoreactive basal keratinocytes. (Aii)-
enlarged area from Ai showing NGF confined to single layer of keratinocytes. (Bi) Painful skin (macromastia patient): NGF-
immunoreactive basal and supra-basal (Bii-arrows) keratinocytes in skin with thin epidermis.Page 7 of 9
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with this explanation, as fibres ran in unusual patterns.
There was no overall change in the sub-epidermal fibre
counts for TRPV1 or the structural nerve marker neurofil-
ament. NGF-immunostaining intensity was similar in the
different groups. However, in some patients, there
appeared to be staining for NGF in the supra-basal epider-
mis in addition to the basal cells, which is usually associ-
ated with inflammation or denervation; increased NGF is
known to cause collateral sprouting [22]. Further studies,
using quantitative NGF assays and in situ hybridisation,
need to be performed to address this issue (these studies
would require more substantial skin biopsies). The men-
strual cycle influences on NGF levels are also difficult to
determine with the current sample size.
Our recent studies have demonstrated increased TRPV1-
immunoreactive nerve fibres in inflammatory bowel dis-
ease [23], and in the mucosal and sub-mucosal layers of
patients with rectal hypersensitivity, where they correlated
with thermal and mechanical hypersensitivity, suggesting
increase of polymodal nociceptors [20]. We proposed that
topical capsaicin or resiniferatoxin treatment, which
reduces the numbers of TRPV1 positive fibres, may be a
useful therapeutic approach in rectal hypersensitivity.
Topical capsaicin has been reported to be useful for treat-
ment for post-mastectomy chronic pain [24], but it is
uncertain if it could substantially help breast pain or ten-
derness in macromastia, as some of the symptoms are
likely to arise from deeper structures. Oral selective TRPV1
antagonists thus deserve consideration: both mechanical
and thermal hyperalgesia may be reversed by capsazepine,
a TRPV1 antagonist [25], again suggesting an effect on
polymodal nociceptors. Thus patients may be helped with
respect to mechanical symptoms, which predominate in
comparison with thermal descriptors.
Little is known of the roles of TRPV3 and TRPV4 in human
pain pathophysiology and keratinocyte function. While
we have previously demonstrated TRPV3 in human sen-
sory neurons [18], no TRPV3 staining was observed in
skin innervation in this study, presumably as the levels in
the periphery were below the detection limit of our
method. It may be speculated that increased TRPV3 and
TRPV4 in observed in keratinocytes may alter keratinocyte
expression of NGF and other molecules, which in turn
may sensitise nociceptors.
Conclusion
Breast pain and tenderness appears to be associated with
abnormal intra-epidermal innervation. This may reflect
re-innervation of skin following nerve stretch damage,
and/or collateral sprouting. While further studies are nec-
essary to establish functional links between the TRPV1,
TRPV3 and TRPV4 immunohistological changes and
breast pain, our findings indicate a path for increasing
understanding and treatment of breast pain.
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